NCT03463473: A Phase I Study of MSB2311 in Advanced Solid Tumors

NCT03463473
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER++, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 1
Drug Category: Immunotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: 
Exclusions: Primary central nervous system (CNS) malignancy or symptomatic CNS metastases- see trial for details
https://ClinicalTrials.gov/show/NCT03463473

Comments are closed.

Up ↑